Early ruxolitinib shows promise in cutting steroids for young GVHD patients
NCT ID NCT06695507
First seen Feb 28, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This study tested whether giving the drug ruxolitinib right away, instead of starting with high-dose steroids, could help children and young adults with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Only one person enrolled before the study was stopped early. The goal was to see if ruxolitinib alone could control the disease and reduce the need for steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
Conditions
Explore the condition pages connected to this study.